Sale

EQS-News: Photon Energy Group Presents Preliminary Results for 2023

Retrieved on: 
Wednesday, March 13, 2024

Amsterdam – 20 February 2024 – Photon Energy N.V. (WSE&PSE: PEN, FSX: A1T9KW) (the ‘Group’ or the ‘Company’) has announced its unaudited financial results for the fourth quarter of 2023 and for the full fiscal year ending 31 December 2023.

Key Points: 
  • Amsterdam – 20 February 2024 – Photon Energy N.V. (WSE&PSE: PEN, FSX: A1T9KW) (the ‘Group’ or the ‘Company’) has announced its unaudited financial results for the fourth quarter of 2023 and for the full fiscal year ending 31 December 2023.
  • ‘We are aware that the results published in this Q4 2023 report are not what we wished for and promised at the beginning of 2023.
  • Despite all these adversities, we managed to achieve the largest increase in generation capacity in the history of Photon Energy Group with overall 35.4 MWp commissioned within a year,’ said Georg Hotar, CEO of Photon Energy Group.
  • Furthermore, on 24 January 2024, EBRD approved the provision of a financing facility to Photon Energy Group in the amount of up to 15 million EUR.

R&S Group acknowledges VERAISON’s decision to gradually return capital to its shareholders

Retrieved on: 
Wednesday, March 13, 2024

Sissach/BL, Switzerland, 8 March 2024 – R&S Group Holding AG (SIX: RSGN) took note of the news release by VERAISON Capital AG (“VERAISON”) published on 7 March 2024 wherein the asset manager informs about its decision to gradually return capital to its shareholders.

Key Points: 
  • Sissach/BL, Switzerland, 8 March 2024 – R&S Group Holding AG (SIX: RSGN) took note of the news release by VERAISON Capital AG (“VERAISON”) published on 7 March 2024 wherein the asset manager informs about its decision to gradually return capital to its shareholders.
  • VERAISON, through its SICAV Engagement Fund, acted as sponsor of the Special Purpose Acquisition Company (“SPAC”) VT5 Acquisition Company AG (“VT5”) which successfully concluded the Initial Business Combination (De-SPAC) with R&S Group at the end of last year.
  • This resulted in the listing of RSGN at SIX Swiss Exchange on 13 December 2023.
  • R&S Group acknowledges VERAISON’s decision to gradually return capital to its shareholders and is prepared to support VERAISON in the sale of their RSGN shares whereby the lock-up commitment shall be maintained.

EQS-News: Logwin 2023 with satisfactory development in a difficult market environment

Retrieved on: 
Wednesday, March 13, 2024

Grevenmacher (Luxembourg) – The Logwin Group achieved a satisfactory revenue and earnings performance in 2023 in a difficult market environment.

Key Points: 
  • Grevenmacher (Luxembourg) – The Logwin Group achieved a satisfactory revenue and earnings performance in 2023 in a difficult market environment.
  • At EUR 91.7m, the operating result (EBITA) in the 2023 financial year was below the previous year (2022: EUR 120.1m) as well.
  • By contrast, the Logwin Group's net result increased to EUR 80.2m thanks to an improved financial result and the reassessment of deferred tax assets.
  • The Logwin Group recorded a cash inflow from operating activities of EUR 107.9m (2022: EUR 169.6m).

EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Retrieved on: 
Wednesday, March 13, 2024

Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.

Key Points: 
  • Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.
  • Key terms of the agreement between Heidelberg Pharma and HCRx:
    Following the receipt by HCRx of a maximum cumulative amount, royalty payments will revert to Heidelberg Pharma and HCRx will receive a low single digit royalty tail percentage thereafter
    Prof. Dr. Andreas Pahl, Chief Executive Officer at Heidelberg Pharma, commented: “We are delighted to partner with HealthCare Royalty.
  • This agreement will provide us with a non-dilutive financing based on expected royalty payments from the worldwide sales of ZircaixTM.
  • Heidelberg Pharma will hold a conference call on 25 March 2024 with the publication of the Annual Report.

EQS-News: Additional share classes offered for GANÉ Value Event Fund, name change effective as of 2 April 2024

Retrieved on: 
Wednesday, March 13, 2024

Additional share classes offered for GANÉ Value Event Fund, name change effective as of 2 April 2024

Key Points: 
  • Additional share classes offered for GANÉ Value Event Fund, name change effective as of 2 April 2024
    The issuer is solely responsible for the content of this announcement.
  • Additional share classes offered for GANÉ Value Event Fund, name change effective as of 2 April 2024
    Aschaffenburg, March 12, 2024.
  • From 2 April 2024, the GANÉ Global Balanced Fund will bear the name “GANÉ Value Event Fund”.
  • The fund was originally launched in December 2023 under the umbrella of GANÉ Investment-AG with sub-funds.

EQS-News: DOUGLAS Group sets price range for its IPO

Retrieved on: 
Wednesday, March 13, 2024

The price range implies a total market capitalization of between 2.8 billion euro and 3.1 billion euro.

Key Points: 
  • The price range implies a total market capitalization of between 2.8 billion euro and 3.1 billion euro.
  • The German Federal Financial Supervisory Authority (BaFin) approved the securities prospectus for the public offer in Germany and listing of DOUGLAS today.
  • With our strong business model and successful growth strategy, the DOUGLAS Group is optimally positioned in a very attractive market.
  • Through Management Equity Programs, the members of the Executive Board as well as current and former managers of the DOUGLAS Group have indirectly invested in the company.

EQS-News: MARKET STUDY: PROPERTY CRISIS? IN MALLORCA, PRICES CONTINUE TO RISE - LUXURY PROPERTIES INCREASED IN PRICE BY 13 PER CENT IN 2023 AND BECAME MORE SCARCE

Retrieved on: 
Wednesday, March 13, 2024

The luxury segment remains the price driver with an increase of 13 per cent.

Key Points: 
  • The luxury segment remains the price driver with an increase of 13 per cent.
  • In the luxury segment, the market is almost empty and experts do not see an end to the price increases.
  • CRES therefore expects property prices to continue to rise in the low single-digit percentage range in the coming years.
  • Porta Mallorquina Real Estate presents the 10th edition of the annual market study "Holiday Property Market Mallorca".

PATRIMOINE ET COMMERCE: 2023 ANNUAL RESULTS

Retrieved on: 
Wednesday, March 13, 2024

»

Key Points: 
  • »
    Patrimoine & Commerce had a sustained leasing activity and signed 58 leases (of which 26 renewals).
  • The collection rate on rents and service charges invoiced in 2023 stands at 98%.
  • In 2023, Patrimoine & Commerce continued to deliver a solid financial performance.
  • For the fiscal year ended December 31, 2023, Patrimoine & Commerce reported consolidated gross rental income of € 50.5m, against € 47.3m for the fiscal year ended December 31, 2022:

EQS-News: H2APEX meets forecast for the fiscal year 2023 and expects revenue to more than double in 2024

Retrieved on: 
Wednesday, March 13, 2024

For the current fiscal year 2024, the company expects its growth course to continue and to more than double its revenue from the previous year to EUR 35 million to EUR 40 million.

Key Points: 
  • For the current fiscal year 2024, the company expects its growth course to continue and to more than double its revenue from the previous year to EUR 35 million to EUR 40 million.
  • In the past fiscal year, we successfully ramped up our business and met our revenues forecast.
  • Accordingly, we plan to achieve positive operating cash flow as early as the coming fiscal year and positive adjusted EBITDA in 2026.
  • H2APEX will publish the final figures and the annual report for the 2023 fiscal year on April 30, 2024.

EQS-News: Group sales revenue 2023 just below, Group EBIT within the most recently announced forecast corridors

Retrieved on: 
Wednesday, March 13, 2024

Group sales revenue 2023 just below, Group EBIT within the most recently announced forecast corridors

Key Points: 
  • Group sales revenue 2023 just below, Group EBIT within the most recently announced forecast corridors
    The issuer is solely responsible for the content of this announcement.
  • Group sales revenue 2023 just below, Group EBIT within the most recently announced forecast corridors
    According to preliminary figures, Group sales of EUR 160.8 million were generated in the financial year 2023 (previous year: EUR 159.2 million).
  • Without this - largely technical - effect, Group EBIT would have been positive at EUR 3.1 million.
  • In this context, we lowered our forecast corridor for Group EBIT to between EUR -4.0 million and EUR -1.0 million.